Cosmos Health Inc. COSM
Nasdaq · XNAS · stock · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Chart by TradingView
5/9
Piotroski F — financial health
-7.92
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $65.3M | -$19.1M | $7.9M | -$8.5M | $18.4M |
| 2024 | $54.4M | -$16.2M | $4.3M | -$8.1M | $24.5M |
| 2023 | $53.4M | -$18.5M | $4.3M | -$16.9M | $36.0M |
| 2022 | $50.3M | -$13.8M | $6.0M | -$14.9M | $39.3M |
| 2021 | $56.2M | -$8.0M | $8.3M | -$7.7M | $4.4M |
| 2020 | $55.4M | $820,786 | $8.1M | -$11.6M | -$4.2M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.92 (distress)
- Working capital / assets 0.002
- Retained earnings / assets -2.034
- EBIT / assets -0.255
- Equity / liabilities 0.392
Source: SEC EDGAR filings · CIK 0001474167 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.